Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. is proposing an underwritten public offering of common stock and warrants to fund research and development activities, working capital, and other corporate purposes [1][2]. Group 1: Offering Details - The offering will include shares of common stock and warrants, all offered by the company [1]. - The final terms of the offering will depend on market conditions, and there is no assurance regarding the completion or size of the offering [2]. - Citizens JMP Securities, LLC is acting as the sole bookrunner for the proposed offering [3]. Group 2: Regulatory Information - The securities will be offered under a shelf registration statement on Form S-3, which was filed with the SEC on January 26, 2022, and became effective on February 2, 2022 [4]. - A preliminary prospectus supplement and base prospectus will be filed with the SEC and will be available on the SEC's website [4]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [6]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [6]. - Reviva has been granted composition of matter patents for both drug candidates in the United States, Europe, and several other countries [6].
Reviva Announces Proposed Public Offering